Autopsy report · NCT05026177
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
Cause of deathFunding or business
“Sponsor decision”
Life of this trial
- Registered 3 months before it started.
- Ran for about 3 years 1 month before it stopped.
- 1,125 participants enrolled.
- Results were posted on the registry 9 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Cassava Sciences, Inc.
- Sponsor type
- Industry
- Conditions
- Alzheimer Disease
- Interventions
- Simufilam; Placebo
- Participants
- 1,125
- Sites
- 89
- Countries
- Canada, Puerto Rico, South Korea, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.